Evaluating the Imperative for Seizure Control in Pregnancy

Maintaining effective seizure control in pregnancy represents a major clinical challenge in modern obstetric neurology. For many years, clinical discussions around pregnant women with epilepsy focused primarily on the teratogenic risks of antiseizure medications. However, robust data quantifying direct fetal risks attributable to maternal seizures remained limited. A multicenter nested case-control study from China has now provided essential insights into this dilemma. The investigators analyzed 1,110 pregnancies across 934 pregnant women with epilepsy. Importantly, the researchers evaluated how breakthrough seizures and clinical deterioration impact composite neonatal outcomes. These primary endpoints encompassed major congenital malformations, neurodevelopmental delay, low birth weight, and fetal death. Consequently, the study clarifies the tangible fetal consequences of uncontrolled maternal epileptic activity. Furthermore, the analysis adjusted for antiseizure medication exposure and maternal folic acid intake. Ultimately, these findings establish that maternal seizures significantly impair neonatal wellbeing independently of medication toxicity. Therefore, achieving maternal seizure stability must remain an uncompromising clinical priority throughout gestation.

Key Findings on Seizure Deterioration and Perinatal Risks

The study reported that 56.6% of participants experienced seizures during pregnancy. In addition, seizure deterioration occurred in 25.9% of pregnancies compared to the prepregnancy baseline. Moreover, 20.9% of women experienced worsening seizure frequency from the first trimester into subsequent trimesters. Multivariate logistic regression revealed that active maternal seizures substantially increased the odds of composite adverse offspring outcomes (adjusted OR 1.472). In particular, severe convulsive manifestations conferred even greater hazards to the fetus. Patients experiencing generalized tonic-clonic seizures showed significantly elevated risks (adjusted OR 1.581). Even more dramatically, maternal status epilepticus nearly tripled the likelihood of adverse neonatal events (adjusted OR 2.906). Furthermore, general seizure deterioration across gestation was associated with an 82.9% rise in composite complications (adjusted OR 1.829). Consequently, loss of seizure control carries profound consequences. Thus, clinicians cannot view breakthrough convulsions during gestation as benign events. Instead, care teams must treat any increase in seizure frequency as an urgent clinical situation requiring prompt therapeutic reassessment.

Trimester-Specific Seizure Patterns and Low Birth Weight

A critical insight from this research involves the timing of maternal seizure episodes across gestation. Specifically, maternal seizures occurring during the second and third trimesters showed a strong statistical correlation with low birth weight. The investigators demonstrated that active seizures during these later trimesters more than doubled this vulnerability (adjusted OR 2.324). Similarly, seizure deterioration emerging in the second or third trimester markedly heightened low birth weight rates (adjusted OR 2.396). Conversely, the study found no direct association between maternal seizures and major congenital malformations. This distinction provides vital clarity for reproductive counseling. Congenital structural anomalies occur during early organogenesis and correlate primarily with specific drug exposures rather than maternal seizures. In contrast, recurrent convulsive episodes in late pregnancy compromise uteroplacental perfusion and trigger transient fetal hypoxemia. Consequently, sustained vascular compromise during critical fetal growth phases contributes directly to intrauterine growth restriction. Therefore, maintaining sustained seizure suppression throughout mid-to-late gestation directly protects fetal somatic growth.

Differentiating ASM Teratogenicity from Seizure-Related Harm

For decades, many pregnant patients with epilepsy discontinued their medications because they feared developmental defects. However, unmonitored drug cessation poses grave danger to both mother and fetus. The recent study emphasizes that while antiseizure medications require careful selection, maternal seizures present distinct pathological hazards. For example, status epilepticus creates systemic acidosis, maternal hypoxia, and severe hemodynamic fluctuations. In addition, generalized tonic-clonic seizures can provoke mechanical abdominal trauma, premature labor, and placental abruption. Contemporary international guidelines emphasize that therapeutic safety involves balancing teratogenic liabilities against seizure recurrence hazards. For instance, high-risk agents like sodium valproate carry documented teratogenic liabilities that justify preconception switches. Conversely, well-tolerated alternatives such as lamotrigine, levetiracetam, and oxcarbazepine offer substantial seizure protection with lower malformation risks. Therefore, maintaining therapeutic drug levels shields the pregnancy from devastating convulsive complications. As a result, optimal obstetric and neurological outcomes depend on treatment adherence rather than premature drug withdrawal.

Clinical Strategies to Maintain Stable Disease Control

Physiological alterations during pregnancy dramatically accelerate antiseizure medication clearance. As plasma volume expands and hepatic metabolism accelerates, free drug concentrations frequently plummet below therapeutic thresholds. Consequently, clinicians must establish a rigorous therapeutic drug monitoring schedule before and throughout gestation. Baseline concentrations should ideally be established prior to conception during a period of sustained seizure remission. Furthermore, clinicians should measure plasma levels monthly during pregnancy, particularly for drugs like lamotrigine and levetiracetam. Whenever drug levels drop by more than 30% from baseline, physicians should promptly increase the dosage. In addition, preconceptional folic acid supplementation remains an indispensable clinical intervention. The evidence highlights that adequate folic acid intake reduces neural tube defect risks and improves maternal-fetal resilience. Healthcare providers must also educate patients on lifestyle factors that trigger breakthrough seizures. For instance, sleep deprivation, gestational hyperemesis, and emotional stress frequently destabilize seizure control. Thus, routine clinical reviews must combine precise pharmacological adjustments with targeted supportive counseling.

Multidisciplinary Protocols for Indian Healthcare Settings

Implementing integrated maternal care pathways is essential within Indian healthcare frameworks. Frequently, pregnant women with epilepsy receive disjointed care across fragmented obstetrics and neurology departments. To resolve these gaps, tertiary centers and community hospitals should establish joint antenatal epilepsy clinics. Additionally, primary care physicians must identify high-risk pregnant patients early and facilitate timely specialist referrals. In rural and semi-urban settings, clinicians must address pervasive social stigma that encourages clandestine treatment cessation. Moreover, healthcare teams must provide continuous access to affordable therapeutic drug monitoring and reliable drug supplies. During labor and delivery, medical staff should maintain continuous fetal heart rate monitoring and secure intravenous access. Furthermore, mothers must continue their regular antiseizure medications throughout active labor to prevent intrapartum convulsions. Following delivery, rapid clearance reversal can trigger postpartum toxicity without dose adjustment. Therefore, postpartum protocols must incorporate structured dose tapering and safe newborn handling guidance for mothers with sleep deprivation.

How do maternal seizures during pregnancy affect the developing fetus?

Maternal seizures, particularly generalized tonic-clonic episodes and status epilepticus, can cause fetal hypoxia, intracranial hemorrhage, and blunt physical trauma from falls. Repeated convulsions in late gestation impair placental perfusion, which directly increases the risk of low birth weight, preterm delivery, and composite adverse neonatal outcomes.

Which antiseizure medications are generally preferred during pregnancy?

Current international consensus guidelines recommend lamotrigine, levetiracetam, and oxcarbazepine as preferred monotherapies during pregnancy. These agents offer favorable teratogenic profiles compared to valproate and topiramate. However, physiological changes during gestation increase their metabolic clearance, requiring clinicians to conduct regular therapeutic drug monitoring to prevent breakthrough seizures.

What role does folic acid supplementation play for pregnant women with epilepsy?

Preconceptional folic acid supplementation is vital for women with epilepsy taking antiseizure medications. Daily supplementation prevents major congenital malformations, including neural tube defects, and may also support optimal neurodevelopment in offspring. Clinicians generally recommend initiating high-dose folic acid prior to conception and continuing through the first trimester.

Disclaimer: This content is for informational and educational purposes only and is not intended as medical advice. Healthcare professionals should make clinical decisions based on each patient's individual profile, multidisciplinary evaluations, and current institutional standards. Refer to the latest local and national guidelines for clinical practice.

References

1. Fu Y et al. Association of seizure control during pregnancy with adverse offspring outcomes in women with epilepsy. J Neurol Neurosurg Psychiatry. 2025 Jun 12. doi: 10.1136/jnnp-2024-335751. PMID: 40175068.


2. Pack AM, et al. Teratogenesis, perinatal, and neurodevelopmental outcomes after in utero exposure to antiseizure medication: Practice guideline update from the AAN, AES, and SMFM. Neurology. 2024;102(11):e209420.


3. Tomson T, et al. Management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on Women and Pregnancy. Epileptic Disord. 2019;21(6):497-517.